Talis Biomedical (TLIS) Stock Price, News & Analysis

Company Overview

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $1.72 to $1.84
• 50-Day Range: $1.57 to $1.85
• 52-Week Range: $1.37 to $9.60
• Volume: 4,473 shs
• Average Volume: 12,840 shs
• Market Capitalization: $3.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TLIS Stock Analysis - Frequently Asked Questions

How have TLIS shares performed this year?

Talis Biomedical's stock was trading at $7.45 at the beginning of the year. Since then, TLIS stock has decreased by 75.3% and is now trading at $1.84.
View the best growth stocks for 2024 here.

How were Talis Biomedical's earnings last quarter?

Talis Biomedical Co. (NASDAQ:TLIS) posted its earnings results on Tuesday, March, 15th. The company reported ($18.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($19.20) by $0.30. Talis Biomedical had a negative net margin of 5,784.73% and a negative trailing twelve-month return on equity of 79.74%.

When did Talis Biomedical's stock split?

Talis Biomedical shares reverse split on the morning of Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Talis Biomedical IPO?

Talis Biomedical (TLIS) raised $150 million in an initial public offering on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager.

Who are Talis Biomedical's major shareholders?

Talis Biomedical's top institutional shareholders include BML Capital Management LLC (13.66%).
View institutional ownership trends.

How do I buy shares of Talis Biomedical?

Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Talis Biomedical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Talis Biomedical investors own include Bloom Energy (BE), SoFi Technologies (SOFI), Athenex (ATNX), Alkaline Water (WTER), Milestone Scientific (MLSS), TherapeuticsMD (TXMD) and Affirm (AFRM).

Company Calendar

• Last Earnings: 3/15/2022
• Today: 12/18/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:TLIS
• CUSIP: N/A
• CIK: 1584751
• Web: talis.bio
• Phone: 650-433-3000
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($28.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-62,010,000.00
• Net Margins: -5,784.73%
• Pretax Margin: -12,506.37%
• Return on Equity: -79.74%
• Return on Assets: -57.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.76
• Quick Ratio: 7.76

Sales & Book Value

• Annual Sales: $300,000.00
• Price / Sales: 11.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $37.95 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 1,823,000
• Free Float: 984,000
• Market Cap: $3.35 million
• Optionable: No Data
• Beta: 1.58